Rajeev Dhere

1.5k citations

60 papers · 868 indexed · h-index 16

Impact in

Health top 5%
- Vaccine Coverage and Hesitancy
Microbiology top 5%
- Bacterial Infections and Vaccines

Papers in ⓘ

Microbiology 11
- Bacterial Infections and Vaccines 9
Virology 6

Co-authors: Prasad S. Kulkarni (17 shared papers)Subhash V. Kapre (7 shared papers)S. S. Jadhav (4 shared papers)Heikki Peltola (1 shared paper)Mikko Paunio (1 shared paper)Sambhaji S. Pisal (10 shared papers)Suresh Jadhav (5 shared papers)Bhagwat Gunale (5 shared papers)
Journals: Vaccine (15 papers)Biologicals (6 papers)Human Vaccines & Immunotherapeutics (5 papers)The Lancet Infectious Diseases (4 papers)Carbohydrate Polymers (3 papers)
Partner nations: India United States United Kingdom

In The Last Decade

Rajeev Dhere

56 papers receiving 845 citations

Peers

Countries citing papers authored by Rajeev Dhere

Since Specialization

Citations

This map shows the geographic impact of Rajeev Dhere's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rajeev Dhere with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rajeev Dhere more than expected).

Fields of papers citing papers by Rajeev Dhere

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rajeev Dhere. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rajeev Dhere. The network helps show where Rajeev Dhere may publish in the future.

Co-authors

The 25 scholars most cited alongside Rajeev Dhere, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Rajeev Dhere Line = papers co-authored together Rajeev Dhere links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 60 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Mumps Outbreaks in Canada and the United States: Time for New Thinking on Mumps Vaccines Clinical Infectious Diseases ·Heikki Peltola, Prasad S. Kulkarni, Subhash V. Kapre, Mikko Paunio, S. S. Jadhav, Rajeev Dhere	2007	107
2	A Randomized, Controlled Trial of an Aerosolized Vaccine against Measles New England Journal of Medicine ·Nicola Low, Ashish Bavdekar, Lakshmanan Jeyaseelan, Siddhivinayak Hirve, Kavitha Ramanathan, Nicholas J. Andrews, Naseem Shaikh, Ramesh Jadi, Arunachalam Rajagopal, Kevin Brown, David Brown, James B. Fink, Oommen John, Pippa Scott, A. Ximena Riveros-Balta, Michel Gréco, Rajeev Dhere, Prasad S. Kulkarni, Ana María Henao-Restrepo	2015	62
3	Comparison of a Novel Human Rabies Monoclonal Antibody to Human Rabies Immunoglobulin for Postexposure Prophylaxis: A Phase 2/3, Randomized, Single-Blind, Noninferiority, Controlled Study Clinical Infectious Diseases ·Nithya Gogtay, Renuka Munshi, D H Ashwath Narayana, B J Mahendra, Vikas D. Kshirsagar, Bhagwat Gunale, Susan M. Moore, Peter Cheslock, Saket Thaker, Siddharth Deshpande, Sunil Karande, Dipti Kumbhar, H S Ravish, B. R. Harish, Sambhaji S. Pisal, Rajeev Dhere, Varsha Parulekar, William C. Blackwelder, Deborah C. Molrine, Prasad S. Kulkarni	2017	60
4	Safety and immunogenicity of dry powder measles vaccine administered by inhalation: A randomized controlled Phase I clinical trial Vaccine ·Sharad Agarkhedkar, Prasad S. Kulkarni, Scott Winston, Robert E. Sievers, Rajeev Dhere, Bhagwat Gunale, K. M. Powell, Paul A. Rota, Mark Papania	2014	50
5	Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study The Lancet Infectious Diseases ·Wilbur H. Chen, Kathleen M. Neuzil, Colleen Boyce, Marcela F. Pasetti, Mardi Reymann, Lionel Martellet, Nancy Hosken, F. Marc LaForce, Rajeev Dhere, Sambhaji S. Pisal, Amol Chaudhari, Prasad S. Kulkarni, Ray Borrow, Helen Findlow, Valerie I. Brown, Megan L McDonough, Len Dally, Mark R. Alderson	2018	50
6	A pandemic influenza vaccine in India: From strain to sale within 12 months Vaccine ·Rajeev Dhere, Leena Yeolekar, Prasad S. Kulkarni, Ravi Menon, Vivek Vaidya, Milan Ganguly, Parikshit Tyagi, Prajak J. Barde, Suresh Jadhav	2011	47
7	Stability of heat stable, live attenuated Rotavirus vaccine (ROTASIIL®) Vaccine ·Sameer P. Naik, Jagdish K Zade, Rajendra N. Sabale, Sambhaji S. Pisal, Ravi Menon, Subhash G. Bankar, Sunil Gairola, Rajeev Dhere	2017	42
8	Bovine rotavirus pentavalent vaccine development in India Vaccine ·Jagdish K Zade, Prasad S. Kulkarni, Sajjad Desai, Rajendra N. Sabale, Sameer P. Naik, Rajeev Dhere	2014	30
9	Mapping antigenic diversity and strain specificity of mumps virus: A bioinformatics approach Virology ·Urmila Kulkarni‐Kale, Janaki Ojha, G. Sunitha Manjari, Deepti D. Deobagkar, Asha D. Mallya, Rajeev Dhere, Subhash V. Kapre	2006	27
10	Seroprevalence of rubella and immunogenicity following rubella vaccination in adolescent girls in India The Journal of Infection in Developing Countries ·Hitt Sharma, V S Padbidri, Subhash V. Kapre, Suresh Jadhav, Rajeev Dhere, Sameer Parekh, Ashok D Dudhane, Sunil Shewale, Gajanan S. Namjoshi	2011	26
11	Development strategy and lessons learned for a 10-valent pneumococcal conjugate vaccine ( PNEUMOSIL® ) Human Vaccines & Immunotherapeutics ·Mark R. Alderson, Vistasp Sethna, Lauren Newhouse, Steve Lamola, Rajeev Dhere	2021	23
12	A post-marketing surveillance study of a human live-virus pandemic influenza A (H1N1) vaccine (Nasovac^®) in India Human Vaccines & Immunotherapeutics ·Prasad S. Kulkarni, Sidram Raut, Rajeev Dhere	2013	22
13	Safety and immunogenicity of a novel 10-valent pneumococcal conjugate vaccine candidate in adults, toddlers, and infants in The Gambia—Results of a phase 1/2 randomized, double-blinded, controlled trial Vaccine ·Ed Clarke, Adedapo Olufemi Bashorun, Michael Okoye, Ama Umesi, Mariama Badjie Hydara, Ikechukwu Adigweme, Rajeev Dhere, Vistasp Sethna, Beate Kampmann, David Goldblatt, Andi Tate, Debra H. Weiner, Jorge Flores, Mark R. Alderson, Steve Lamola	2019	18
14	Process development and immunogenicity studies on a serogroup ‘X’ Meningococcal polysaccharide conjugate vaccine Biologicals ·Srinivas Reddy Chilukuri, P.Amala Reddy, Nikhil Avalaskar, Asha D. Mallya, Sambhaji S. Pisal, Rajeev Dhere	2014	18
15	Reaching international GMP standards for vaccine production: challenges for developing countries Expert Review of Vaccines ·Julie B. Milstien, Alejandro Costa, Suresh Jadhav, Rajeev Dhere	2009	18
16	Isolation of a High Affinity Neutralizing Monoclonal Antibody against 2009 Pandemic H1N1 Virus That Binds at the ‘Sa’ Antigenic Site PLoS ONE ·Nachiket Shembekar, Vamsee Mallajosyula, Arpita Mishra, Leena Yeolekar, Rajeev Dhere, Subhash V. Kapre, Raghavan Varadarajan, Gupta Sk	2013	15
17	Ultraviolet-C irradiation for inactivation of viruses in foetal bovine serum Vaccine ·Vivek Vaidya, Rajeev Dhere, Snehal Agnihotri, Ravindra Muley, Sanjay B. Patil, Amit Pawar	2018	15
18	Persistence of Antibodies Induced by Measles-Mumps-Rubella Vaccine in Children in India Clinical and Vaccine Immunology ·Sidram Raut, Prasad S. Kulkarni, Mrudula Phadke, S. S. Jadhav, Subhash V. Kapre, Rajeev Dhere, Sanjay P. Dhorje, S. R. Godse	2007	15
19	Persistence of Antibodies Induced by Measles-Mumps-Rubella Vaccine in Children in India Clinical and Vaccine Immunology ·Sidram Raut, Prasad S. Kulkarni, Mrudula Phadke, S. S. Jadhav, Subhash V. Kapre, Rajeev Dhere, Sanjay P. Dhorje, S. R. Godse	2008	15
20	Meningococcal Serogroup ACWYX Conjugate Vaccine in Malian Toddlers New England Journal of Medicine ·Milagritos D. Tapia, Samba O. Sow, Abdi Naficy, Fatoumata Diallo, Fadima Cheick Haidara, Amol Chaudhari, Lionel Martellet, Awa Traoré, Kelly Townsend‐Payne, Ray Borrow, Nancy Hosken, Igor Smolenov, Sambhaji S. Pisal, F. Marc LaForce, Rajeev Dhere, Dhananjay Kapse, Yuxiao Tang, Mark R. Alderson, Prasad S. Kulkarni	2021	14

About Rajeev Dhere

Rajeev Dhere is a scholar working on Microbiology, Virology, Health, Epidemiology and Infectious Diseases, having authored 60 papers that have together received 868 indexed citations. Recurring topics across this work include Pneumonia and Respiratory Infections (17 papers), Virology and Viral Diseases (15 papers), Influenza Virus Research Studies (11 papers), Vaccine Coverage and Hesitancy (10 papers), SARS-CoV-2 and COVID-19 Research (10 papers), Respiratory viral infections research (10 papers), Bacterial Infections and Vaccines (9 papers) and Viral gastroenteritis research and epidemiology (8 papers). The work is most often cited by research in Health (168 citations), Microbiology (119 citations), Infectious Diseases (339 citations), Virology (75 citations) and Epidemiology (500 citations). Rajeev Dhere has collaborated with scholars based in India, United States and United Kingdom. Frequent co-authors include Prasad S. Kulkarni, Subhash V. Kapre, S. S. Jadhav, Heikki Peltola, Mikko Paunio, Sambhaji S. Pisal, Suresh Jadhav, Bhagwat Gunale, Ravi Menon and Mark R. Alderson. Their work appears in journals such as Vaccine, Biologicals, Human Vaccines & Immunotherapeutics, The Lancet Infectious Diseases and Carbohydrate Polymers.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact